Fujifilm Biotechnologies is unveiling a precision purification tool, ShunzymeX, that simplifies downstream processing for ...

Healthcare around the world depends on the production of pure biopharmaceuticals. To be effective, those purification processes must be fast, robust, and affordable. By using non-affinity-based ...

ShunzymeX addresses inherent challenges in traditional microbial downstream purification due to microbial-expressed protein diversity.

FUJIFILM Biotechnologies introduces ShunzymeX precision purification technology for downstream processing of complex biologics: Teessid, United Kingdom Thursday, March 5, 2026, 16 ...

The rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based ...

In search of the next generation chromatographic technique for antibody purification, our team has developed an affinity chromatography method using the unconventional nucleotide binding site (NBS).

Affinity chromatography theoretically does just that—a ligand that specifically interacts with the target protein is immobilized on a chromatography matrix; the target protein binds to the column, and ...

The non-binding MOU contemplates the purchase and delivery of the unit pursuant to the terms of a Total System Performance License (TSPL). The term of the TSPL is three years, with automatic renewals ...